Joe Cornicelli oversees the design, execution, and analysis of studies to assess therapeutic efficacy in animal models of disease. His department offers models of acute and chronic diabetes, dyslipidemia, and atherosclerosis.
Prior to joining Charles River, Joe was with Warner-Lambert/Pfizer for more than 22 years, where he rose to become a Research Fellow. During his tenure, he led numerous discovery teams and served on the atorvastatin (Lipitor) development team. He also led the in vivo effort for the registration of troglitazone, the first PPAR-γ agonist approved for the treatment of type II diabetes. Dr. Cornicelli is a Fellow of the American Heart Association, and serves as a reviewer for various journals.
His research has appeared in more than 40 peer-reviewed papers and yielded four patents.